Rhythm Pharmaceuticals is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
TypePublic
HQBoston, US
Founded2008
Size (employees)22 (est)+23%
Websiterhythmtx.com
Rhythm Pharmaceuticals was founded in 2008 and is headquartered in Boston, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Rhythm Pharmaceuticals

Keith Gottesdiener

Keith Gottesdiener

CEO

Rhythm Pharmaceuticals Office Locations

Rhythm Pharmaceuticals has an office in Boston
Show all (1)
Report incorrect company information

Rhythm Pharmaceuticals Financials and Metrics

Rhythm Pharmaceuticals Revenue

USD

Net income (Q3, 2017)

(10 m)

EBIT (Q3, 2017)

(8.3 m)

Market capitalization (20-Sep-2018)

1.1 b

Closing stock price (20-Sep-2018)

31.1

Cash (30-Sep-2017)

27.9 m
Rhythm Pharmaceuticals's current market capitalization is $1.1 b.
Annual
USDFY, 2015FY, 2016

General and administrative expense

3.4 m6.3 m

R&D expense

7.1 m19.6 m

Operating expense total

10.6 m25.9 m

EBIT

(10.6 m)(25.9 m)
Quarterly
USDQ3, 2016Q3, 2017

General and administrative expense

982 k2.3 m

R&D expense

5.4 m6 m

Operating expense total

6.4 m8.3 m

EBIT

(6.4 m)(8.3 m)
Annual
USDFY, 2015FY, 2016

Cash

34.9 m6.5 m

Prepaid Expenses

623 k638 k

Current Assets

35.5 m11.2 m

PP&E

17 k930 k
Quarterly
USDQ2, 2017Q3, 2017

Cash

8.7 m27.9 m

Prepaid Expenses

722 k1.6 m

Current Assets

18.5 m32 m

PP&E

822 k845 k
Annual
USDFY, 2015FY, 2016

Net Income

(11.1 m)(25.9 m)

Depreciation and Amortization

144 k

Accounts Payable

893 k467 k

Cash From Operating Activities

(7 m)(23.2 m)
Quarterly
USDQ2, 2016Q3, 2016Q2, 2017Q3, 2017

Net Income

(11.1 m)(17.5 m)(13.2 m)(23.2 m)

Depreciation and Amortization

33 k89 k108 k163 k

Accounts Payable

882 k(335 k)(602 k)830 k

Cash From Operating Activities

(12.6 m)(17 m)(13.2 m)(21.6 m)
USDY, 2017

Financial Leverage

-0.7 x
Show all financial metrics
Report incorrect company information

Rhythm Pharmaceuticals News and Updates

Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference

BOSTON, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Executive…

Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results

-- Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Pro-opiomelanocortin (POMC) and Leptin Receptor (LEPR) Deficiency Obesity -- -- Announced New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Geneti…

VC-backed Rhythm Pharmaceuticals goes public

Boston-based Rhythm Pharmaceuticals Inc, a developer of peptide therapeutics that treats rare genetic deficiencies, has debuted its IPO after pricing its over 7 million shares at $17 per share. The stock began trading October 5, 2017 on the NASDAQ under the ticker symbol "RYTM." Morgan Stanley, BofA…
Report incorrect company information

Rhythm Pharmaceuticals Company Life and Culture

Report incorrect company information